Go Pro
→ A letter from Shannon Stansberry (From Porter & Company) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Asterias Biotherapeutics Inc stock logo
AST
Asterias Biotherapeutics
$0.00
$0.00
$0.51
▼
$2.05
$111KN/A136,653 shs1,000 shs
DNAPrint Genomics Inc. stock logo
DNAG
DNAPrint Genomics
$0.00
$0.00
▼
$0.00
N/AN/AN/AN/A
NephroGenex, Inc stock logo
NRXGQ
NephroGenex
$0.00
$0.00
▼
$0.21
$36KN/A26,223 shs2,000 shs
RSPID
RespireRx Pharmaceuticals
$0.00
+28.6%		$0.00
$0.01
▼
$1.50
$130K0.15928,930 shs300 shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover
7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Asterias Biotherapeutics Inc stock logo
AST
Asterias Biotherapeutics
0.00%0.00%0.00%0.00%0.00%
DNAPrint Genomics Inc. stock logo
DNAG
DNAPrint Genomics
0.00%0.00%0.00%0.00%+12.00%
NephroGenex, Inc stock logo
NRXGQ
NephroGenex
0.00%0.00%0.00%0.00%0.00%
RSPID
RespireRx Pharmaceuticals
0.00%0.00%0.00%0.00%+20.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Asterias Biotherapeutics Inc stock logo
AST
Asterias Biotherapeutics
$0.00
$0.00
$0.51
▼
$2.05
$111KN/A136,653 shs1,000 shs
DNAPrint Genomics Inc. stock logo
DNAG
DNAPrint Genomics
$0.00
$0.00
▼
$0.00
N/AN/AN/AN/A
NephroGenex, Inc stock logo
NRXGQ
NephroGenex
$0.00
$0.00
▼
$0.21
$36KN/A26,223 shs2,000 shs
RSPID
RespireRx Pharmaceuticals
$0.00
+28.6%		$0.00
$0.01
▼
$1.50
$130K0.15928,930 shs300 shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover
7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Asterias Biotherapeutics Inc stock logo
AST
Asterias Biotherapeutics
0.00%0.00%0.00%0.00%0.00%
DNAPrint Genomics Inc. stock logo
DNAG
DNAPrint Genomics
0.00%0.00%0.00%0.00%+12.00%
NephroGenex, Inc stock logo
NRXGQ
NephroGenex
0.00%0.00%0.00%0.00%0.00%
RSPID
RespireRx Pharmaceuticals
0.00%0.00%0.00%0.00%+20.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Asterias Biotherapeutics Inc stock logo
AST
Asterias Biotherapeutics
0.00
N/AN/AN/A
DNAPrint Genomics Inc. stock logo
DNAG
DNAPrint Genomics
0.00
N/AN/AN/A
NephroGenex, Inc stock logo
NRXGQ
NephroGenex
0.00
N/AN/AN/A
RSPID
RespireRx Pharmaceuticals
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Asterias Biotherapeutics Inc stock logo
AST
Asterias Biotherapeutics
N/AN/AN/AN/AN/AN/A
DNAPrint Genomics Inc. stock logo
DNAG
DNAPrint Genomics
N/AN/AN/AN/AN/AN/A
NephroGenex, Inc stock logo
NRXGQ
NephroGenex
N/AN/AN/AN/AN/AN/A
RSPID
RespireRx Pharmaceuticals
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Asterias Biotherapeutics Inc stock logo
AST
Asterias Biotherapeutics
N/AN/AN/AN/AN/AN/AN/AN/AN/A
DNAPrint Genomics Inc. stock logo
DNAG
DNAPrint Genomics
N/AN/AN/AN/AN/AN/AN/AN/AN/A
NephroGenex, Inc stock logo
NRXGQ
NephroGenex
N/AN/AN/AN/AN/AN/AN/AN/AN/A
RSPID
RespireRx Pharmaceuticals
N/A-$3.20N/AN/AN/AN/AN/AN/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Asterias Biotherapeutics Inc stock logo
AST
Asterias Biotherapeutics
N/AN/AN/AN/AN/A
DNAPrint Genomics Inc. stock logo
DNAG
DNAPrint Genomics
N/AN/AN/AN/AN/A
NephroGenex, Inc stock logo
NRXGQ
NephroGenex
N/AN/AN/AN/AN/A
RSPID
RespireRx Pharmaceuticals
N/AN/AN/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Asterias Biotherapeutics Inc stock logo
AST
Asterias Biotherapeutics
N/A
DNAPrint Genomics Inc. stock logo
DNAG
DNAPrint Genomics
N/A
NephroGenex, Inc stock logo
NRXGQ
NephroGenex
N/A
RSPID
RespireRx Pharmaceuticals
N/A

Insider Ownership

CompanyInsider Ownership
Asterias Biotherapeutics Inc stock logo
AST
Asterias Biotherapeutics
N/A
DNAPrint Genomics Inc. stock logo
DNAG
DNAPrint Genomics
N/A
NephroGenex, Inc stock logo
NRXGQ
NephroGenex
N/A
RSPID
RespireRx Pharmaceuticals
50.03%
CompanyEmployeesShares OutstandingFree FloatOptionable
Asterias Biotherapeutics Inc stock logo
AST
Asterias Biotherapeutics
N/A55.66 millionN/ANot Optionable
DNAPrint Genomics Inc. stock logo
DNAG
DNAPrint Genomics
241.29 billionN/ANot Optionable
NephroGenex, Inc stock logo
NRXGQ
NephroGenex
1,70012.95 millionN/ANot Optionable
RSPID
RespireRx Pharmaceuticals
272.27 millionN/ANot Optionable

Recent News About These Companies

No headlines for this company have been tracked by MarketBeat.com

Top Headlines

View All Headlines
NVIDIA logo displayed on a computer chip surrounded by illuminated green circuit board traces.
NVIDIA’s Rally Sets Up a Bigger Test Ahead of Earnings
By Thomas Hughes | August 11, 2026
A quantum computing processor glows inside a gold-plated dilution refrigerator in a research laboratory.
The Quantum Race Is Heating Up—And 2 Small Players Stand Out
By Nathan Reiff | August 17, 2026
The Metals Company logo displayed over an image of polymetallic nodules on the seafloor with sea stars.
The Metals Company’s Big Bet Now Comes Down to a License
By Thomas Hughes | August 16, 2026
SoundHound AI logo displayed within a glowing orange ring against a dark background with light wave effects.
SoundHound AI Sends a Loud Signal After Its Q2 Earnings Beat
By Thomas Hughes | August 10, 2026
Illustration of a satellite beaming signal to a smartphone and cell tower above a city skyline at dusk.
Space Race Meets Ground Reality for Tower REITs
By Jeffrey Neal Johnson | September 1, 2026
Asterias Biotherapeutics stock logo

Asterias Biotherapeutics NYSEAMERICAN:AST

$0.0020 0.00 (0.00%)
As of 07/10/2019

Asterias Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing cell-based therapeutics to treat neurological conditions associated with demyelination, and cellular immunotherapies to treat cancer. Its clinical stage programs include AST-OPC1, an oligodendrocyte progenitor cell population derived from pluripotent stem cells that is in Phase I/IIa clinical trial for spinal cord injuries; AST-VAC2 is a non-patient-specific cancer immunotherapy derived from pluripotent stem cells for the treatment of non-small cell lung cancer; and AST-VAC1, a patient-specific cancer immunotherapy that has completed Phase II clinical trial for the treatment of acute myeloid leukemia. The company was formerly known as BioTime Acquisition Corporation and changed its name to Asterias Biotherapeutics, Inc. in March 2013. Asterias Biotherapeutics, Inc. was founded in 2012 and is headquartered in Fremont, California.

DNAPrint Genomics stock logo

DNAPrint Genomics OTCMKTS:DNAG

DNAPrint Genomics, Inc. engages in the development and marketing of genetic testing products and services. It offers AncestryByDNA, a pan-chromosomal assay for genetic ancestry; EurasianDNA, which measures European sub-ancestry; EuropeanDNA, which reports a customer's proportional basic continental European ancestry; DNAWitness to determine genetic heritage from DNA samples obtained from crime scenes; RETINOME, which provides a physical portrait of a person of interest for a detective based on a DNA sample from a crime scene or remains of an individual; RETINOME, which allows infer eye color from DNA; and GenomeLab SNPstream Genotyping System, which offers genotyping rates and uses a multiplexing format to generate data with the minimum of reagents. The company serves forensic science, genealogical research, consumer products, and pharmaceutical development clients. DNAPrint Genomics, Inc. was formerly known as Lexington Energy, Inc. The company was incorporated in 1983 and is based in Sarasota, Florida with a subsidiary in Leverkusen, Germany.

NephroGenex stock logo

NephroGenex OTCMKTS:NRXGQ

NephroGenex, Inc. is a pharmaceutical company. The Company is focused on the development of therapeutics to treat kidney disease. The Company has paused the clinical program of its product candidate, oral Pyridorin, for the treatment of diabetic nephropathy. The Company was primarily focused on the Phase III Pyridorin program, and other planned clinical and nonclinical studies and other work needed to submit Pyridorin for acute kidney injury (AKI), as well as the treatment of diabetic nephropathy in patients with Type II diabetes for regulatory approval in the United States and Europe. The Company has not generated any revenues.

RespireRx Pharmaceuticals OTCMKTS:RSPID

$0.0018 +0.00 (+28.57%)
As of 11/7/2025

RespireRx Pharmaceuticals Inc. engages in the discovery and development of pharmaceuticals for the treatment of respiratory disorders. It has two drug platforms comprising ampakines, which are small molecule compounds to enhance the excitatory actions of the neurotransmitter glutamate at the alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor complex; and cannabinoids, primarily dronabinol, a synthetic derivative for use in refractory chemotherapy-induced nausea and vomiting, as well as for anorexia in patients with AIDS. The company's lead ampakine, CX1739, which is in Phase II clinical studies for drug-induced respiratory depression (RD), as well as for central sleep apnea. It is also developing CX717, CX1739, and CX1942 that have clinical application in the treatment of CNS-driven respiratory disorders, neurobehavioral disorders, spinal cord injury, neurological diseases, and orphan indications. The company was formerly known as Cortex Pharmaceuticals, Inc. and changed its name to RespireRx Pharmaceuticals Inc. in December 2015. RespireRx Pharmaceuticals Inc. was founded in 1987 and is headquartered in Glen Rock, New Jersey.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas